Arecor Therapeutics (FRA:6UI) Ending Cash Position: €3.43 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6UI Arecor Therapeutics PLC FRA:6UI
37 GF Score
Price €0.63
GF Value €0.45
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics Ending Cash Position?

Arecor Therapeutics FRA:6UI -3.08% 37 Ending Cash Position is €3.43 Mil as of Dec. 2025. GuruFocus rates FRA:6UI with a GF Score™ of 37/100 and a GF Value™ of €0.45. The stock has 6 warning signs investors should review.

Arecor Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 was €3.43 Mil.

Arecor Therapeutics's quarterly Ending Cash Position declined from Dec. 2024 (€3.91 Mil) to Jun. 2025 (€2.20 Mil) but then increased from Jun. 2025 (€2.20 Mil) to Dec. 2025 (€3.43 Mil).

Arecor Therapeutics's annual Ending Cash Position declined from Dec. 2023 (€5.91 Mil) to Dec. 2024 (€3.91 Mil) and declined from Dec. 2024 (€3.91 Mil) to Dec. 2025 (€3.43 Mil).

Arecor Therapeutics Ending Cash Position Related Terms

Arecor Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Arecor Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arecor Therapeutics Ending Cash Position Chart

Arecor Therapeutics Annual Data
Trend May17 May18 May19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 21.56 5.48 5.91 3.91 3.43

Arecor Therapeutics Semi-Annual Data
May17 May18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.91 2.99 3.91 2.20 3.43
FRA:6UI
37GF Score
Arecor Therapeutics PLC FRA:6UI
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arecor Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Arecor Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.702+-0.271
=3.43

Arecor Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2.135+1.296
=3.43

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €3.43 Mil mean?
Arecor Therapeutics (FRA:6UI) has a Ending Cash Position of €3.43 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Arecor Therapeutics and its competitors.
Is Arecor Therapeutics' Ending Cash Position too high?
Arecor Therapeutics' current Ending Cash Position is €3.43 Mil. Overall, Arecor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Ending Cash Position compare to VRTX and REGN?
Arecor Therapeutics' Ending Cash Position of €3.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Arecor Therapeutics and its competitors. Arecor Therapeutics's current Ending Cash Position is €3.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (FRA:6UI) has a current Ending Cash Position of €3.43 Mil. The stock's GF Value™ is €0.45, compared to a current price of €0.63 — trading 40% above its estimated fair value. The current Ending Cash Position is €3.43 Mil. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Arecor Therapeutics (FRA:6UI), the current Ending Cash Position is €3.43 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arecor Therapeutics (FRA:6UI) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of €0.63 is trading 40% above its estimated GF Value™ of €0.45.

Key valuation signals for FRA:6UI:

  • Ending Cash Position: €3.43 Mil
  • GF Value™: €0.45 vs. price of €0.63 (40% above fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the FRA:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arecor Therapeutics Business Description

Other Exchanges AREC:UK6UI:Germany
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score

Get the complete analysis for FRA:6UI

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.63
Price
€0.45
GF Value